Giredestrant significantly improved IDFS over SOC endocrine therapy, reducing the risk of invasive disease recurrence or ...

Emmy-winning journalist and author Suleika Jaouad recently delivered the keynote address at the inaugural Blood Cancer Heroes celebration. The event, held in partnership with Bloo ...

Trodelvy did not show statistically significant PFS improvement over chemotherapy in hormone-receptor-positive/HER2-negative breast cancer post-endocrine therapy. Investigator-assessed PFS showed a ...

Standard-of-care treatment with Janus kinase inhibitor monotherapy improves splenomegaly and symptom burden but provides ...

“In our real-world experience, [Yescarta] in relapsed or refractory follicular lymphoma showed durable responses and a ...

In a recent interview with CURE, Dr. Kai Tsao broke down current treatment advancements for patients with prostate cancer.

Epkinly combined with GemOx achieved durable remissions in relapsed/refractory DLBCL, addressing unmet needs in second-line ...

Emphasis on accessible, low-toxicity treatments, including oral therapies, to reduce financial burden and improve patient ...

Accurate information about Lynch syndrome is essential. As more people discuss hereditary cancer online, misinformation ...

Orlowski serves as chairman, Ad Interim, and director of Myeloma in the Departments of Lymphoma/Myeloma and Experimental ...

Jaypirca significantly improved progression-free survival in treatment-naive CLL/SLL, reducing disease progression or death risk by 80% compared to BR. The 24-month progression-free survival rate was ...

The oncologist's innovative thinking and deep knowledge provided hope and improved the patient's quality of life. I’ve lived ...